Kornimate/medical-research-clean huggingface dataset:
effect of galactose on permeblity factor in patients with fsgs and ckd stage 5

Conditions: Focal Segmental Glomerulosclerosis

Summary: this study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant fsgs.

patients with resistant fsgs have persistent proteinuria and a high risk of progression to end stage kidney disease (eskd). a circulating factor that increases glomerular permeability to albumin (palb) has been detected in over 50% of these patients. while the molecular identity of the factor has not been fully established, in vitro studies and limited clinical experience suggest that galactose can reduce the level of the fsgs permeability factor. this study is a pilot study to determine if oral administration of galactose can lower the circulating level of the fsgs permeability factor. five patients with biopsy proven primary fsgs - native or transplant kidney, receiving plasmapheresis - who are resistant to steroids and one other immunosuppressive agents will be studied. the only eligibility factor is presence of the fsgs permeability factor. the experimental intervention is administration of galactose, orally, 0.2 g/kg body weight/dose twice daily. the duration of treatment will be 28 days,. patients will be seen on days 0, 14, and 28 of treatment. they will be seen at week 8, 16 and 24 after discontinuation of the galactose. physical examination and routine laboratory tests (smac, cbc, urine protein:creatinine ratio in an early morning sample) will be done at each visit. the fsgs permeability factor will be assayed at days 0 and 28 of treatment and 6 months after discontinuation of the galactose. the permeability factor will be tested in the laboratory of virginia savin md (medical college of wisconsin) using previously described methods. all other treatments will be unchanged during the 28 day oral galactose treatment period. the study will be analyzed based on the number of patients in whom the fsgs permeability factor is lowered to normal levels.

Eligibility criteria:
inclusion criteria: * primary fsgs * ckd stage 5 * resistance to steroids and another immunosuppressive medication exclusion criteria: * secondary fsgs

Keywords: fsgs permeability factor galactose primary fsgs, resistant to immunosuppressive medication
fatty acid oxidation disorders & body weight regulation grant

Conditions: Trifunctional Protein Deficiency

Summary: several hormones involved in body weight regulation increase the subject's ability to burn fat for energy. the purpose of this study is to investigate how burning fat for energy may affect those hormones and body weight in children. the study will also determine if eating a diet higher in protein alters the amount of fat you burn and how these hormones control body weight.

a role for mitochondrial fatty acid oxidation in the peripheral signaling cascade of leptin, adiponectin and insulin has recently been proposed from animal studies but has not been investigated in humans. children with trifunctional protein (tfp, including deficiency of long-chain hydroxyacyl-coa dehydrogenase) and very long-chain acyl-coa dehydrogenase (vlcad) deficiency, inherited disorders of long-chain fatty acid ß-oxidation, lack an ability to oxidize fatty acids for energy. they have increased levels of body fat and circulating leptin and a high incidence of obesity. current therapy for children with these disorders is based on frequent meals and consuming a low fat, very high carbohydrate diet. despite treatment, exercise induced rhabdomyolysis is a common complication of tfp and vlcad deficiency that frequently leads to exercise avoidance. the effects of these genetic defects on body composition and weight regulation have not been investigated. the contribution of fatty-acid oxidation during moderate intensity exercise in children has also not been reported. two groups of subjects were recruited: one group of subjects had a long-chain fatty acid oxidation disorder (n=13). the other group is a group of controls (n=16). we studied peripheral signals of body weight regulation, glucose tolerance, body composition, and exercise metabolism in subjects with a long-chain fatty acid oxidation disorder compared to normal controls.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of tfp, lchad, cpt2 or vlcad deficiency * at least 7 years of age * willingness to complete overnight admission * generally healthy exclusion criteria: * inclusion in another research project that alters macronutrient intake * diabetes, thyroid disease or other endocrine dysfunction that alters body composition. * pregnancy * anemia

Keywords: trifunctional protein deficiency tfp weight regulation
a description of inflammatory cell types in moderate to severe pediatric asthma: eosinophilic and non eosinophilic sputum markers while on anti-ige therapy

Conditions: ALLERGIC ASTHMA

Summary: the researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ecp), neutrophils il-8) before and while on anti-ige therapy in a pediatric population of moderate to severe asthmatics who have ongoing persistent asthma symptoms despite on moderate to high doses of inhaled corticosteroids (ics). associations will be assessed between the types of sputum inflammatory markers and the patient's atopic status and level of asthma control as indicated by the following measures: 1. pulmonary function test (pft) 2. asthma symptoms based on the asthma control test (act)

objectives: primary: describe inflammatory cell types in study patients and compare changes in inflammatory cell patterns before and during anti-ige therapy. secondary:describe patterns of sputum eosinophilia and neutrophilia in relation to asthma symptom improvement based on act and pft hypotheses: differences in inflammatory response after the addition of anti-ige therapy can be described in neutrophilic, eosinophilic and neutrophilic/eosinophilic asthmatics. neutrophilic asthmatics patients will fail to respond when placed on anti-ige while eosinophilic asthmatics will respond well. sputum inflammatory markers are sensitive markers of inflammation and can predict response to new asthma treatment modalities such as anti-ige therapy.

Eligibility criteria:
inclusion criteria: * moderate to severe allergic asthma, uncontrolled on conventional therapy exclusion criteria: * history of systemic illness, currently on other immune modulators like immunotherapy, ivig * pregnancy * ige level \>1300
the success of pediatric percutaneous nephrolithotomy

Conditions: Nephrolithiasis

Summary: between june 1997-june 2018, 573 pediatric patients underwent pcnl for renal stone disease by senior surgeons. data was disunited into 2 groups. the study showed that pcnl is an operator-dependent procedure, with the improvement of outcomes over time, presumably due to increased operator experience and the involvement of a team member with substantial prior experience during 20 years, by gaining experience and with the development of new tools and optics, fluoroscopy time, operation time, blood loss and complication rates decreased and stone-free rates increased.


Eligibility criteria:
inclusion criteria: * pediatric patients with kidney stone exclusion criteria: * patients with a solitary kidney

Keywords: urolithiasis pediatrics percutaneous
effect of walking exercise training on adherence to disease management and metabolic control in diabetes

Conditions: Diabetes Mellitus, Type 2; Exercise; Walking Pneumonia; Diabetes

Summary: this study aims to determine the effects of a transtheoretical model-based walking exercise training and disease management and metabolic control in patients with type 2 diabetes. this randomized controlled trial will be conducted as a pre-test and post-test experiment with 30 intervention and 30 control individuals. the intervention group will receive the transtheoretical model-based exercise training. the intervention group will be followed-up for 6 months (from 0 to 6 months) to determine the patients' behavioral changes after the training will be completed.

this study aims to determine the effects of a transtheoretical model-based walking exercise training and disease management and metabolic control in patients with type 2 diabetes. this randomized controlled trial will be conducted as a pre-test and post-test experimental model with 30 intervention and 30 control individuals. the intervention group will receive the transtheoretical model-based exercise training. data will be collected using patient a identification form, patient compliance scale to the treatment of type 2 diabetes mellitus, transtheoretical model scales, pedometer and metabolic outcomes. data will be analyzed by using chi square, two-way anova to determine the difference between two or more independent/dependent groups and spearman's correlation to determine the relationship between two groups.

Eligibility criteria:
inclusion criteria: patients who diagnosed with type 2 diabetes at least 6 months. received insulin and/or oral antidiabetic treatment, literate, and having no communication problems, between the ages of 18 and 65, whose arterial blood pressure is in range of systolic ≤ 160mmhg and diastolic ≤ 100mmhg, who had hba1c between 7-9 % will be included in the study. the patients who agree to participate in the study (voluntarily) and who have no objection to exercising with cardiology consultation will be included in the study. exclusion criteria: participants with diabetes-related (severe) complications and diabetic foot, pregnancy, diagnosed with cancer, having physical and mental problems that prevent walking will be excluded from the study. ha1c over 9 - despite the treatment (will be referred to the doctor for treatment change). patients with blood sugar above 300 - despite treatment (will be referred to their doctor for a change in treatment).

Keywords: diabetes mellitus, type 2 transtheoritical model walking exercise
the study of acupuncture on vascular and functional neuroimaging in parkinson's disease patients with sleep disorders

Conditions: Acupuncture; Parkinson's Disease; Sleep Disorders; Neuroimaging

Summary: the purpose of the study is to compare vascular and functional neurological changes of acupuncture in patients with parkinson's disease and sleep disorders. in the randomized controlled clinical trial study, patients meeting the criteria for inclusion will be randomly enrolled and divided into two groups in a 1:1 ratio: the acupuncture group and the sham acupuncture group. the intervention is going to be executed using the acupoints gv14（dazhui）and gb20 (fengchi).the acupuncture needles will be inserted to a depth of 0.8 to 1 cm using gv14（dazhui）and gb20 (fengchi) in the acupuncture group. the sham acupuncture group's needles will be inserted to a depth of 0.1 to 0.2 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points.during the study, researchers will observe changes in cerebral blood vessels and neuroimaging before and after acupuncture in the two groups. using multimodal fusion advanced vascular-neuronal imaging techniques could evaluate the effect of acupuncture on brain blood vessels and function in patients with parkinson's disease and sleep disorders and provide an objective neuroimaging basis for assessing the effectiveness of acupuncture.

neuroimaging assessment:subjects are keeping awake, resting flat on the examination table, using rubber earplugs to reduce noise, using foam headbands to fix head movement artifacts, closing eyes to calm breathing, fixing the head and minimizing head and other parts of the initiative and passive exercise.at the same time, it is required not to carry out any thinking activities. after the subject is familiar with the environment, it begins to scan and conduct a comprehensive mri scan before and after the acupuncture needling.

Eligibility criteria:
inclusion criteria: 1. meeting the above diagnostic criteria for parkinson's disease and sleep disorders; 2. hoehn-yahr grade 2-3; 3. those who voluntarily participate in the project while he/she or his/her guardian sign an informed consent form; 4. those who have had a junior high school education or above and have a correct understanding of clinical acupuncture research significance. exclusion criteria: 1. accompanied with sleep apnea syndrome, sleep-behavioral disorders such as sleep-breathing disorders, and other system diseases that cause sleep disorders, such as anemia and other hematological diseases, hypothyroidism, severe heart and lung diseases, tumors, liver and kidney diseases; 2. history of drug use or alcohol addiction, psychosis and sedation for painful illnesses; 3. severe cognitive impairments and failure to complete scale assessments; 4. there are barriers to communication and communication that affect the evaluation of research, such as speech, vision, hearing and other serious damage to patients; 5. allergic to needles or alcohol; 6. those who cannot perform mri scans, such as claustrophobia.
effects of mexiletine on colonic transit in a patient with irritable bowel syndrome - constipation (ibs-c)

Conditions: IBS

Summary: to understand if mexiletine will restores normal colonic motility in a patient with irritable bowel syndrome - constipation (ibs-c) and a genetic mutation in scn5a.

to understand if mexiletine will restore normal colonic motility in a patient with a missense mutation in scn5a, which encodes a voltage-sensitive sodium channel nav1.5 as it is known to rescue certain expression defects of nav1.5 in vitro.

Eligibility criteria:
inclusion criteria: * established ibs diagnosis with a known a997t mutation in nav1.5t exclusion criteria: * normal 48-hour baseline transit study * current use of mexiletine * inability to stay in rochester for 9 days for testing * known allergy to mexiletine * inability to complete daily diary * taking a medication known to affect myotonia, had a coexisting neuromuscular disease, or had another serious medical illness including second- or third-degree heart block, atrial flutter, atrial fibrillation, ventricular arrhythmia, history of cardiac arrhythmia requiring medication, congestive heart failure, symptomatic cardiomyopathy, or symptomatic coronary artery disease * inability to withdraw medications known to interact with mexiletine. patient is currently not on any of these medications

Keywords: ibs
clinical hypnosis before external cephalic version (ecv)

Conditions: Breech Presentation at Term

Summary: does clinical hypnosis or neuro-linguistic programming improve the success rate of external cephalic version?

prospective off-center randomisation of clinical hypnosis or neuro-linguistic programming intervention prior to a external cephalic version treatment.

Eligibility criteria:
inclusion criteria: * singleton * breech presentation * gestation age above 36 weeks + 6 days exclusion criteria: * multiples * cannot understand german language

Keywords: breech presentation at term pregnancy external cephalic version (ecv) clinical hypnosis neuro-linguistic programming (nlp)
therapeutic efficacy of categorical language fluency smartphone game application

Conditions: Mild Cognitive Impairment; Alzheimer's Disease

Summary: the purpose of this study is to examine therapeutic efficacy of categorical language fluency smartphone game application in mild cognitive impairment and mild alzheimer's dementia.

the categorical language fluency smartphone game application was developed based on the semantic distance training, which was effective in improving categorical language fluency of mild cognitive impairment and mild alzheimer's dementia. 10 patients with mild cognitive impairment and another 10 patients with mild alzheimer's dementia were recruited to examine therapeutic efficacy of the application.

Eligibility criteria:
inclusion criteria: * aged above 55 * confirmed literacy * diagnosed to mild cognitive impairment by international working group on mild cognitive impairment and clinical dementia rating(cdr) of 0 or 0.5. * diagnosed to possible or probable alzheimer's dementia by nincds-adrda and clinical dementia rating(cdr) of 1 or below. exclusion criteria: * evidence of delirium, confusion * any neurological conditions causing cognitive decline such as parkinson's disease, brain hemorrhage, brain tumor, normal pressure hydrocephalus * evidence of severe cerebrovascular pathology * history of loss-of-consciousness over 1 hour due to head trauma or repetitive head trauma of mild severity * history of substance abuse or dependence such as alcohol * presence of depressive symptoms that could influence cognitive function * presence of medical comorbidities that could result in cognitive decline

Keywords: mild cognitive impairment cognitive rehabilitation cognitive therapy alzheimer's disease memory enhancement categorical language fluency
high peep application following pulmonary thromboendarterectomy; does it have any impact on outcome?

Conditions: Reperfusion Injury After Pulmonary Thromboendarterektomy

Summary: investigation of the effect of intraoperative lung protection high peep maneuver on ischemic reperfusion injury in patients undergoing pulmonary endarterectomy.

chronic thromboembolic pulmonary hypertension (cteph) is a rare disease characterized by progression of thromboembolism obstructing pulmonary arteries as an organized tissue. pulmonary thromboendarterectomy (pte) is a treatment option for chronic thromboembolic pulmonary disease. however, pte is associated with specific postoperative complications, such as pulmonary edema and right ventricular failure due to reperfusion injury, with a significant mortality rate of 7% to 24%. some strategies have been proposed to reduce lung injury after pte, such as rectification maneuvers and high peep. the aim of this study was to investigate the effect of intraoperative lung protection high peep maneuver in patients undergoing pulmonary endarterectomy for ischemic reperfusion injury.

Eligibility criteria:
inclusion criteria: * patients undergoing elective pte operation due to cteph, * 20-70 years old exclusion criteria: * patients with chronic inflammatory disease, * liver and renal failure, * heart failure (\<ef: 40%), * intraoperative bronchial hemorrhage, * patients undergoing postoperative revision.

Keywords: chronic thromboembolic pulmonary hypertension peep reperfusion injury
prognostic impact of delta-haemolysin production deficiency in staphylococcus aureus on the prognosis of infected implant treated by dair

Conditions: Bone and Joint Infection; Staphylococcus Aureus

Summary: the aim of this study is to determine if delta-haemolysin production deficiency of staphylococcus aureus is a marker in favour of chronic infections on implants


Eligibility criteria:
inclusion criteria: * patients having implant infection due to s. aureus treated by dair exclusion criteria: * none

Keywords: bone and joint infection staphylococcus aureus chronic infection
impact of tele-visit on patients continous positive airway pressure (cpap) follow-up by home care provider

Conditions: Obstructive Sleep Apnea

Summary: to determine the impact of telecare on continous positive airway pressure (cpap) patients follow up by home care provider (hcp)

obstructive sleep apnea (osa) syndrome is a chronic respiratory pathology affecting 4% of french adult population and reference treatment for moderate to severe forms of obstructive sleep apnea syndrome (osa) is continuous positive airway pressure (cpap). however, cpap treatment is binding, so nearly a quarter of patients abandoning treatment at 1 year and nearly half of them at 3 years. support for these patients on cpap must therefore be optimal and seek patient satisfaction; hcp (home care provider) plays an important role in this follow-up. since 2018 in france, teleconsultation entered on common law but was little used. the pandemic has disrupted the habits of care and patients monitoring by developing remote monitoring. home care providers (hcp) have also been forced to organize remote monitoring, particularly for the annual follow-up visit (technical tele-visit). the impact of the annual follow-up visits of hcp by tele-visit has never been clinically evaluated. if its clinical relevance were demonstrated and patient satisfaction confirmed, this follow-up modality could become, like telecare, a new standard for the follow-up of patients on cpap.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * cpap ≥ 12 months and annual followed by "agir à dom" health care provider. * compliance with cpap ≥ 4h/night and ahi ≤ 5 events/hour on machine report for the 3 months prior to inclusion exclusion criteria: * follow-up by agir à dom. for an other service than package f9.1 : cpap follow-up and remote monitoring * unacceptable level of mask leakage * patient unavailable or willing to move within the next 12 months to an area not covered by agir à dom. * patient considered by the investigator to be unfit for a tele-visit

Keywords: tele-visit
comparative study of gamma-hydroxy butyrate versus oxazepam in the treatment of alcohol withdrawal syndrome

Conditions: Alcohol Withdrawal Syndrome; Alcohol Dependence

Summary: benzodiazepines (bdzs) are the gold standard in the treatment of alcohol withdrawal syndrome (aws). gamma-hydroxybutyric acid also known as sodium oxybate (smo) has been tested as a treatment for aws with encouraging results. aim of this phase iv, multicenter randomized double-blind, double dummy study is to evaluate the efficacy of smo in comparison to oxazepam in the treatment of alcohol withdrawal symptoms (aws).

this is a phase iv, multicenter randomized (1:1), active drug-controlled study (double-blind, double dummy) with parallel groups evaluating the efficacy of smo versus oxazepam in the treatment of aws in alcohol-dependent patients. a placebo-controlled design was considered but excluded, given that a gold standard treatment for aws is available (i.e., bdzs). furthermore, considering that smo and oxazepam have two different pharmaceutical formulation (suspension and tablets, respectively), a double-dummy design was adopted. thus, all subjects will receive both medications, tablets (oxazepam or placebo) and suspension (smo or placebo), at the same time.

Eligibility criteria:
inclusion criteria: * age range 21-75, * diagnosis of alcohol dependence according to dsm-iv criteria * the presence of aws as assessed by clinical institute withdrawal assessment for alcohol-revised (ciwa-ar) scale, a scoring system for quantitative evaluation of physical symptoms of aws.20 only subjects with a ciwa-ar score equal to or higher than 10 (defined as moderate or severe aws requiring pharmacological treatment) were ultimately enrolled in the study. exclusion criteria: * ≤55 kg of body weight; * history of withdrawal fits within 24 hours pre-study; * history of epilepsy or epileptics seizures not properly controlled by established anti-epileptic treatment; * dependence from narcotics, bdzs or other drugs of abuse; * documented pre-existent hypersensitivity to smo or to bdzs, * renal failure (blood creatinine \>2•5 mg/dl and/or documented proteinuria \>500 mg/die), * heart failure, * severe respiratory failure * hepatic encephalopathy stage ii-iv; * psychiatric disorders requiring treatment with psychoactive medications before the start of the study; * treatment with clonidine, haloperidol, bromocriptine during the last 3 months prior to participation in the study; * participation to other clinical investigations in the previous month prior to recruitment; * females whose could not assure not to become pregnant during the 1 month period of treatment, and during the subsequent 3 weeks; * subjects without a stable social condition or homeless.

Keywords: alcohol withdrawal syndrome treatment sodium oxybate oxazepam